19:35 , Jan 24, 2019 |  BC Innovations  |  Emerging Company Profile

Cabaletta’s CAAR Ts for autoimmunity

Cabaletta Bio Inc.’s CAAR T therapy is geared to treat B cell-mediated autoimmunity without wiping out all B cells. The company is betting an antigen-specific approach will yield efficacy without CARs’ safety drawbacks. Cabaletta spun...
19:06 , Jan 4, 2019 |  BC Week In Review  |  Financial News

Venture roundup: Cabaletta, Thousand Oaks, Sojournix

Autoimmune company Cabaletta Bio Inc. (Radnor, Pa.), CMC services play Thousand Oaks Biopharmaceuticals Inc. (Haimen, China) and women's health company Sojournix Inc. (Waltham, Mass.) each announced venture rounds of at least $44 million on Jan....
22:05 , Jan 3, 2019 |  BC Extra  |  Financial News

Venture roundup: Cabaletta, Thousand Oaks, Sojournix

Autoimmune company Cabaletta Bio Inc. (Radnor, Pa.), CMC services play Thousand Oaks Biopharmaceuticals Inc. (Haimen, China) and women's health company Sojournix Inc. (Waltham, Mass.) each announced venture rounds of at least $44 million on Thursday....
18:30 , Nov 9, 2018 |  BC Week In Review  |  Financial News

Cabaletta spins out of Penn with CAR T autoimmune therapy, $38M series A

University of Pennsylvania spinout Cabaletta Bio Inc. (Radnor, Pa.) emerged from stealth with an untranched $38 million series A to develop CAR T therapies for B cell-mediated autoimmune diseases. Cabaletta's co-founders include Michael Milone, an...
20:09 , Nov 8, 2018 |  BC Extra  |  Financial News

Cabaletta spins out of Penn with CAR T autoimmune therapy, $38M series A

University of Pennsylvania spinout Cabaletta Bio Inc. (Radnor, Pa.) emerged from stealth with an untranched $38 million series A to develop CAR T therapies for B cell-mediated autoimmune diseases. Cabaletta's co-founders include Michael Milone, an...
07:00 , Jul 21, 2016 |  BC Innovations  |  Tools & Techniques

A new route for CARs

By retooling chimeric antigen receptor (CAR) T cell technology to kill autoimmune cells rather than tumor cells, a University of Pennsylvania team is creating therapies for autoimmune diseases to be as effective as those for...
07:00 , Jul 21, 2016 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Desmoglein 3 (DSG3)

Autoimmune disease INDICATION: Pemphigus vulgaris (PV) Cell culture and mouse studies suggest chimeric autoantigen receptor (CAAR) T cells specific for DSG3 could help treat PV. The DSG3 CAAR T cells consisted of human T cells...
08:00 , Jan 31, 2013 |  BC Innovations  |  Distillery Therapeutics

Indication: Autoimmune disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Autoimmune disease Pemphigus vulgaris (PV) Desmoglein 1 (DSG1); DSG3 In vitro and mouse studies identified a DSG-binding peptide that could help treat PV. In a mouse...
08:00 , Nov 13, 2006 |  BC Week In Review  |  Company News

Peptimmune, Orphan Europe deal

Peptimmune granted Orphan Europe an exclusive license to develop and commercialize PI-0824 to treat pemphigus vulgaris in Europe, the Middle East and Africa. Peptimmune retains rights in all other territories. The synthetic peptide derived from...
07:00 , Oct 13, 2003 |  BC Week In Review  |  Clinical News

PI-0824: Phase I

Peptimmune started a U.S. and Israeli Phase I trial in 15-21 patients. Peptimmune Inc. , Cambridge, Mass.   Product: PI-0824   Business: Dermatology   Molecular target: NA   Description: Synthetic peptide derived from desmoglein 3...